Malecare Cancer Support's Advanced Prostate Cancer Program invites you to our teleconference on Provenge. The Teleconference will begin 6PM EDT, Monday, June 13, 2011. Please register at http://bit.ly/kKuByH Call in number and code will be emailed to you, along with info on how to ask your specific question of our guest. The teleconference will be [...]
Dr Aaron Katz and Dr. Philippa J. Cheetham from the Columbia University Medical Center in New York City are hosting a men’s health seminar on Father’s Day weekend, specifically on Saturday, June 18, 2011. Both Drs. Katz and Cheetham are board certified urological surgeons who specialize in the treatment of prostate cancer. You can also [...]
There are no right or wrong answers for men with prostate cancer when trying to decide what treatment to have, or even if they want to have treatment. One vital piece of information that is often left out of the equation is the chance of dying from prostate cancer if a man chooses not to [...]
Today’s big news is about a media release made yesterday by Centocor Ortho Biotech with the official and final results of the Phase III clinical trial of abiraterone acetate (Zytiga™) plus prednisone vs. prednisone alone in men with metastatic, castration-resistant prostate cancer (mCRPC) who have already received at least one course of a docetaxel based [...]
Recent data presented at the 2011 Genitourinary Cancers Symposium supports the growing consensus that intermittent androgen suppression (IADT) is no less effective than continuous androgen suppression at treating men with prostate cancer that recurs after radiotherapy. Lead investigator, Laurence Klotz, MD, chief of urology, Sunnybrook Health Sciences Center, and professor of surgery at the University [...]